Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

R. Cummings, Steven; Ferrari, Serge; Eastell, Richard; Gilchrist, Nigel; Beck Jensen, Jens‐Erik; R. McClung, Michael; Roux, Christian; Törring, Ove; Valter, Ivo; T Wang, Andrea; P. Brown, Jacques

doi:10.1002/jbmr.3337

Public

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

Shared by NobleBlocks on Nov 4, 2017 • 12:00 AM UTC

Authors:

Steven R. Cummings

Serge Ferrari

Richard Eastell

Abstract

Denosumab reduces bone resorption and vertebral and nonvertebral fracture risk. Denosumab discontinuation increases bone turnover markers 3 months after a scheduled dose is omitted, reaching above-baseline levels by 6 months, and decreases bone mineral density (BMD) to baseline levels by 12 months. ...

Subject

Denosumab

Medicine

Discontinuation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!